CClinicalTrials.gg
CompletedNCT07261865DISCOVERUpdated May 4, 2026

Identifying Diabetes and Impaired Glucose Tolerance in ICU Patients

An observational study in Diabetes (DM) and Critical Illness, sponsored by University Medical Center Groningen. Completed at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by University Medical Center Groningen · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,198
Ages
18 Years and older
Sex
All
01

Study summary

In the Netherlands, patients admitted to the ICU are classified as having diabetes based on whether their medical records indicate glucose management medication use (Dutch National Intensive Care Evaluation (NICE) Registry). However, this approach does not identify patients with 1) undiagnosed diabetes, 2) uncontrolled diabetes, 3) patients managing their condition through lifestyle modifications, or 4) individuals with prediabetes, which is considered an early stage of diabetes. Consequently, this may lead to an underestimation of the "true" prevalence of chronic dysglycaemia among ICU patients and as a result the impact of various glycaemic states on acute outcomes remain underexplored.

Read the detailed description

Diabetes is one of the most common comorbidities among patients admitted to the intensive care unit. Previous studies have found that patients with diabetes are at higher risk of severe complications including infections, delayed wound healing, cardiovascular events and ultimately death while in the ICU.

In the Netherlands, patients admitted to the ICU are classified as having diabetes based on whether their medical records indicate glucose management medication use (Dutch National Intensive Care Evaluation (NICE) Registry). However, this approach does not identify patients with 1) undiagnosed diabetes, 2) uncontrolled diabetes, 3) patients managing their condition through lifestyle modifications, or 4) individuals with prediabetes, which is considered an early stage of diabetes. Consequently, this may lead to an underestimation of the prevalence of chronic dysglycaemia among ICU patients. Therefore, the "true" prevalence and impact of various glycaemic states in ICU patients and how they influence acute and long-term outcomes remain underexplored. Within the general Dutch population, diabetes is diagnosed in 7% of individuals, while approximately 30% of those aged over 45 have prediabetes. In the ICU, 17% of admitted patients require medication for diabetes management, highlighting a higher prevalence compared to the general population's 7%. Given that most patients (\~87%) admitted to the ICU are older than 45 years, it is likely that the prevalence of prediabetes is elevated in ICU patients as well. It is essential to avoid underestimating the incidence of diabetes and impaired glucose tolerance to ensure that patients are managed properly during ICU stay and importantly after leaving the ICU. Diabetes diagnosis typically relies on (fasting) glucose levels yet diagnosing diabetes in ICU patients poses challenges due to stress and acute illness impacting blood glucose levels, leading to stress-induced hyperglycaemia. The investigators found that upon admission to the ICU, 77% of patients without diabetes exhibited high blood glucose levels, with 20% of these patients experiencing severe hyperglycaemia. The underlying cause of this hyperglycaemia is currently uncertain, but it may stem from acute critical illness, the effect of medications, previously undiagnosed diabetes or prediabetes, or a combination of these factors.

Since the investigators are currently unable to accurately determine if patients entering the ICU have diabetes or prediabetes using standard glucose measurements, measuring glycated haemoglobin (HbA1c) which reflects the average blood glucose levels over the past two or three months may be an alternative method which together with anthropometric, glycaemic parameters, and other metabolic traits will assist in assessing the risk of associated complications and the impact on organ injury. Given the rising incidence of diabetes in the general population, there is an increasing likelihood that a greater number of individuals will be admitted to the ICU with diabetes and prediabetes in the coming years. Moreover, the prevalence and impact of various glycaemic states in ICU patients and how they influence acute critical illness outcomes remain underexplored.

02

Conditions studied

  • Diabetes (DM)
  • Critical Illness

Keywords

  • Critical Illness
  • Diabetes
  • DISCOVER
03

In context

Diabetes Mellitus

10,923 studies on the registry are indexed under Diabetes Mellitus; 1,318 are open to participants now.

This study's enrollment of 4,198 is above the median of 233 across 2,218 observational studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

University Medical Center Groningen is the lead sponsor of 609 studies on the registry; 174 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All adult patients admitted to the ICU

Inclusion criteria

  • All adult patients admitted to the ICU

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,198 participants (actual)
Target follow-up
3 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. What is the prevalence of the various dysglycemic states in patients admitted to the ICU?

    HbA1c 6%=normal, 6-6.4%=prediabetes, \>6.5%=diabetes

    Time frame: Day 1

  2. What is the impact of chronic hyperglycemic states on acute (ICU mortality and organ injury) and long-term outcomes?

    ICU mortality, organ injury during ICU stay (Acute Kidney Injury defined by the KDIGO criteria), and 1-year mortality

    Time frame: Up to 1 year

Secondary outcomes

  1. Impact of relative dysglycemia

    What is the impact of relative dysglycemia (glycemic ratio) on acute (mortality, organ injury) and long-term outcomes (1-year mortality)

    Time frame: Up to 1-year

07

Study locations

2 sites
  • Frisius MC
    Leeuwarden, Provincie Friesland 8934AD, Netherlands
  • University Medical Center Groningen
    Groningen, Provincie Groningen 9713GZ, Netherlands
08

References and documents

Publications

  • Luethi N, Cioccari L, Tanaka A, Kar P, Giersch E, Deane AM, Martensson J, Bellomo R. Glycated Hemoglobin A1c Levels Are Not Affected by Critical Illness. Crit Care Med. 2016 Sep;44(9):1692-4. doi: 10.1097/CCM.0000000000001656. PubMed 26977855 ↗
  • Yong PH, Weinberg L, Torkamani N, Churilov L, Robbins RJ, Ma R, Bellomo R, Lam QT, Burns JD, Hart GK, Lew JF, Martensson J, Story D, Motley AN, Johnson D, Zajac JD, Ekinci EI. The Presence of Diabetes and Higher HbA1c Are Independently Associated With Adverse Outcomes After Surgery. Diabetes Care. 2018 Jun;41(6):1172-1179. doi: 10.2337/dc17-2304. Epub 2018 Mar 26. PubMed 29581095 ↗
  • Torkamani N, Churilov L, Robbins R, Jerums G, Beik V, Radcliffe N, Patterson S, Bellomo R, Burns J, Hart GK, Lam Q, Power DA, MacIsaac RJ, Johnson DF, Zajac J, Ekinci EI. Diabetes and higher HbA1c levels are independently associated with adverse renal outcomes in inpatients following multiple hospital admissions. J Diabetes Complications. 2020 Jan;34(1):107465. doi: 10.1016/j.jdiacomp.2019.107465. Epub 2019 Oct 22. PubMed 31735639 ↗
  • Michalia M, Kompoti M, Koutsikou A, Paridou A, Giannopoulou P, Trikka-Graphakos E, Clouva-Molyvdas P. Diabetes mellitus is an independent risk factor for ICU-acquired bloodstream infections. Intensive Care Med. 2009 Mar;35(3):448-54. doi: 10.1007/s00134-008-1288-0. Epub 2008 Sep 20. PubMed 18807006 ↗
  • Carpenter DL, Gregg SR, Xu K, Buchman TG, Coopersmith CM. Prevalence and Impact of Unknown Diabetes in the ICU. Crit Care Med. 2015 Dec;43(12):e541-50. doi: 10.1097/CCM.0000000000001353. PubMed 26465219 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07261865
Lead sponsor
University Medical Center Groningen
Collaborators
Frisius Medisch Centrum
Responsible party
Jill Moser (Assistant Professor, University Medical Center Groningen) — Principal investigator
First posted
Dec 3, 2025
Start date
May 1, 2024
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
May 4, 2026

Study contacts

Jill Moser, PhD
principal investigator · University Medical Center Groningen

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion